Glutathione Supplements: What Human Trials Report

Glutathione supplements are orally taken capsules, tablets, powders or liquids containing the tripeptide glutathione (often labelled reduced glutathione or GSH), and the human evidence summarised here is limited to the specific trials cited on this page. This page does not repeat the general background on what the molecule is or what it is marketed for; that material sits in the glutathione glossary entry and in what is glutathione used for. What follows is a population by population look at published human trials: who was studied, what the comparator was, which endpoint was measured, and what the investigators reported.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any supplement, medication or health decision.

Regulatory status in the United States

In the United States, oral glutathione products are marketed as dietary supplements. Dietary supplements are not reviewed or approved by the Food and Drug Administration for safety and effectiveness before they are sold, and manufacturers, not the agency, are responsible for substantiating label claims. That regulatory category is separate from prescription medicines and from any intravenous or injectable preparation, which falls under different rules entirely. No glutathione product holds FDA approval for skin lightening.

The practical consequence for readers of the literature is that the existence of a product on a shelf carries no statement about whether a trial endpoint was met. The sections below describe only what published trials measured.

The absorption question and what blood and tissue measurements showed

The central scientific question about oral glutathione is whether an intact tripeptide survives digestion well enough to raise glutathione concentrations in the body. The most direct human test of that question in the verified literature is a randomised, double blind, placebo controlled trial in which 54 non smoking adults received oral glutathione at 250 mg per day or 1000 mg per day, or placebo, for 6 months, with glutathione measured in blood, erythrocytes, plasma, lymphocytes and buccal cells (PMID 24791752). Researchers reported dose dependent increases in glutathione in blood and in the tissue compartments sampled after 6 months of supplementation, with the largest proportional change observed in buccal cells, and the study also reported that levels declined toward baseline after supplementation stopped during a washout period (PMID 24791752).

That single trial is the main reason the older assumption that oral glutathione cannot raise body stores at all is now treated as unsettled rather than closed. It does not, by itself, establish that raising measured glutathione changes any clinical outcome. Biomarker movement and clinical benefit are separate endpoints, and the trials described below that used clinical endpoints did not consistently report benefit.

Human trials at a glance

Healthy adults: body stores as the endpoint

The 6 month randomised trial in healthy adults is the clearest example of a trial designed around a pharmacological question rather than a disease outcome (PMID 24791752). Its design features matter when the result is interpreted: participants were non smokers, the comparator was placebo, the dosing period was long by supplement trial standards, and multiple tissue compartments were sampled rather than plasma alone (PMID 24791752). The study did not enrol a diseased population and was not powered to detect clinical events, so it speaks to availability and not to therapeutic value.

Cystic fibrosis: a clinical endpoint that was not met

A multicentre, randomised, placebo controlled, double blind trial examined oral glutathione in children with cystic fibrosis using growth as the outcome of interest, and the researchers reported that oral glutathione did not improve growth compared with placebo (PMID 32960827). That trial is informative precisely because it tested a hard, objectively measured clinical endpoint in a population with a well described oxidative stress burden, and reported a null result (PMID 32960827). Null trials of this type are frequently absent from promotional summaries of glutathione, which makes them worth reading alongside biomarker studies.

Type 2 diabetes: microbiome composition

A separate line of human work examined what long term oral glutathione supplementation did to the gut microbiome of individuals with type 2 diabetes, and the investigators reported changes in gut microbial composition associated with supplementation (PMID 37935462). Microbiome composition is a descriptive endpoint; a reported shift in bacterial taxa is not the same as a reported change in glycaemic control, symptoms or complications, and the cited report should not be read as describing a clinical outcome (PMID 37935462).

Skin pigmentation endpoints in the cited literature

A randomised, double blinded, benchmark and placebo controlled trial tested oral L cystine associated with reduced L glutathione on human skin pigmentation and reported reductions in measured pigmentation relative to placebo (PMID 33834608). Because the tested product combined cystine with glutathione, the trial design cannot attribute any observed change to glutathione alone, and the inclusion of an active benchmark arm means the comparison of interest was partly against an established agent rather than placebo only (PMID 33834608).

A 12 week randomized, double blind, placebo controlled trial in healthy women compared oral reduced glutathione at 250 mg per day, oral oxidized glutathione at 250 mg per day and placebo, and reported that melanin index and ultraviolet spots tended to be lower in both glutathione arms, with fewer wrinkles at some sites in the reduced form arm (PMID 28490897). As stated above, no glutathione product holds FDA approval for skin lightening.

Oral, liposomal and sublingual forms

Formulation is often presented as the decisive variable for glutathione products, on the argument that liposomal encapsulation or sublingual absorption bypasses intestinal breakdown. The verified human trials summarised on this page used conventional oral administration: the 6 month body stores trial administered oral glutathione capsules (PMID 24791752), the cystic fibrosis trial administered oral glutathione against placebo (PMID 32960827), the diabetes microbiome work used long term oral supplementation (PMID 37935462), and the pigmentation trial used an oral cystine plus glutathione combination (PMID 33834608). None of the trials cited on this page compared a liposomal or sublingual preparation against a conventional oral capsule in humans, so claims that one of those formats outperforms another cannot be supported from this citation set. The 12 week skin trial likewise gave reduced and oxidized glutathione by mouth and did not test a liposomal or sublingual form (PMID 28490897).

Adverse Events in Glutathione Trials: What Studies Report

Tolerability information in this citation set is thin and specific to the populations studied. In the 6 month randomised trial of oral glutathione at 250 mg and 1000 mg daily, the researchers described the supplementation as well tolerated over the study period (PMID 24791752). The multicentre cystic fibrosis trial was conducted as a placebo controlled, double blind study with safety monitoring and reported no growth benefit for oral glutathione over placebo (PMID 32960827). The 12 week skin trial collected blood samples for safety monitoring and reported no serious adverse effects in either glutathione arm (PMID 28490897). A fuller treatment of reported adverse events appears in glutathione side effects: what studies report.

What the evidence base does and does not establish

• Measured glutathione can rise with sustained oral dosing. A placebo controlled 6 month trial reported dose dependent increases in blood and tissue glutathione in healthy adults (PMID 24791752).
• A biomarker change did not translate into a clinical endpoint in every population. The randomised cystic fibrosis trial reported no growth advantage over placebo (PMID 32960827).
• Some endpoints are descriptive only. Reported gut microbiome shifts in type 2 diabetes describe composition, not clinical outcomes (PMID 37935462).
• Skin findings come from a combination product. The pigmentation trial tested cystine together with glutathione, so single ingredient attribution is not possible (PMID 33834608).
• The literature is small. Only a handful of human trials are cited here, each in a single population, such as healthy women followed for 12 weeks (PMID 28490897).

Trial sizes in this set are modest, durations range from weeks to months, and the populations differ enormously, from healthy non smokers to children with a genetic disease. Results reported in one of those groups do not transfer automatically to another, and none of the cited trials was designed to answer questions about long term use beyond its own study window.

Related reading

• Glutathione: glossary definition
• What is glutathione used for
• Glutathione side effects: what studies report

References

• Randomized controlled trial of oral glutathione supplementation on body stores of glutathione (European Journal of Nutrition, 2015)
• Glutathione and its antiaging and antimelanogenic effects (Clinical, Cosmetic and Investigational Dermatology, 2017)
• The effects of the oral supplementation of L-Cystine associated with reduced L-Glutathione-GSH on human skin pigmentation: a randomized, double-blinded, benchmark- and placebo-controlled clinical trial (Journal of Cosmetic Dermatology, 2022)
• Oral Glutathione and Growth in Cystic Fibrosis: A Multicenter, Randomized, Placebo-controlled, Double-blind Trial (Journal of Pediatric Gastroenterology and Nutrition, 2020)
• Effect of long-term oral glutathione supplementation on gut microbiome of type 2 diabetic individuals (FEMS Microbiology Letters, 2023)